Drug reference

Macrogol 3350 with anhydrous sodium sulfate, ascorbic acid, potassium chloride, sodium ascorbate and sodium chloride

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 77

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

MOVIPREP ® Bowel cleansing [before any procedure requiring a clean bowel] ▶BY MOUTH ▶Adult: 1 litre daily for 2 doses; ﬁrst dose of reconstituted solution taken on the evening before procedure and the second dose on the morning of procedure, alternatively 2 litres daily for 1 dose; reconstituted solution to be taken on the evening before the procedure, or on the morning of the procedure, treatment should be completed at least 1 hour before clinical procedures conducted without general anaesthesia, and at least 2 hours before clinical procedures conducted under general anaesthesia PLENVU ® Bowel cleansing [before any procedure requiring a clean bowel] ▶BY MOUTH ▶Adult: 500 mL daily for 2 doses; ﬁrst dose of reconstituted solution taken on the evening before procedure and the second dose on the morning of procedure, alternatively 1 litre daily in 2 divided doses, reconstituted solution to be taken either on the evening before the procedure, or in the morning of the procedure—separate doses by at least 1 hour, treatment should be completed at least 1 hour before clinical procedures conducted without general anaesthesia, and at least 2 hours before clinical procedures conducted under general anaesthesia

PDF page 77

Contra Indications

Disorders of gastric emptying. G6PD deﬁciency. gastrointestinal obstruction. gastrointestinal perforation. ileus. toxic megacolon

PDF page 77

Cautions

Debilitated patients. dehydration (correct before administration). impaired consciousness. impaired gag reﬂex or possibility of regurgitation or aspiration. moderate-to-severe cardiac impairment. patients at risk of arrhythmia (including those with thyroid disease or electrolyte imbalance). severe acute inﬂammatory bowel disease

PDF page 77

Prescribing And Dispensing Information

PLENVU ® Dose 1 (single sachet) when reconstituted up to 500 mL with water provides Na+ 160.9 mmol, K+ 13.3 mmol, Cl- 47.6 mmol; Dose 2 (sachets A and B) when reconstituted up to 500 mL with water provides Na+ 297.6 mmol, K+ 16.1 mmol, Cl- 70.9 mmol. MOVIPREP ® 1 pair of sachets (A+B) when reconstituted up to 1 litre with water provides Na+ 181.6 mmol (Na+ 56.2 mmol absorbable), K+ 14.2 mmol, Cl– 59.8 mmol.

PDF page 77

Safety

Interactions

→Appendix 1: bowel cleansing preparations

PDF page 77

Side Effects

▶Common or very common Chills. dehydration. dizziness. fever. gastrointestinal discomfort. headaches. hunger. malaise. nausea. sleep disorder. thirst. vomiting ▶Uncommon Arrhythmias. asthenia. drowsiness. dry mouth. dry throat. dysphagia. electrolyte imbalance. hot ﬂush. pain. palpitations. temperature sensation altered ▶Frequency not known Flatulence. hyponatraemic seizure SIDE-EFFECTS, FURTHER INFORMATION Abdominal pain is usually transient and can be reduced by taking preparation more slowly.

PDF page 77

Pregnancy

Manufacturer advises use only if essential— no or limited information available.

PDF page 77

Breast Feeding

Manufacturer advises use only if essential—no information available.

PDF page 77

Renal Impairment

Manufacturer advises caution if eGFR less than 30 mL/minute/1.73 m2.

PDF page 77

Monitoring Requirements

Manufacturer advises consider monitoring baseline and post-treatment electrolytes, renal function and ECG as appropriate, in Gastro-intestinal system debilitated patients, those with signiﬁcant renal impairment, arrhythmia, or at risk of electrolyte imbalance.

PDF page 77

Dose and formulations

Directions For Administration

PLENVU ® Manufacturer advises the contents of the single sachet for Dose 1 should be made up to 500 mL with water and taken over 30 minutes; the contents of the 2 sachets (A and B) for Dose 2 should be made up to 500 mL with water and taken over 30 minutes. Each dose should be followed by 500 mL of clear ﬂuid taken over 30 minutes. MOVIPREP ® Manufacturer advises one pair of sachets (A and B) should be made up to 1 litre with water and taken over 1–2 hours; 1 litre of other clear ﬂuid should also be taken during treatment.

PDF page 77

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Oral powder CAUTIONARY AND ADVISORY LABELS 10, 13 EXCIPIENTS: May contain Aspartame ELECTROLYTES: May contain Chloride, potassium, sodium ▶Moviprep (Forum Health Products Ltd) Moviprep oral powder sachets sugar-free | 4 sachet p £10.36 ▶Plenvu (Forum Health Products Ltd) Plenvu oral powder sachets sugar-free | 3 sachet p £12.43

PDF page 77

Clinical care

Patient And Carer Advice

Manufacturer advises solid food should not be taken during treatment until procedure completed.

PDF page 77

Dose text by age group

Adult

1 litre daily for 2 doses; ﬁrst dose of

First-line fragment. Read the complete Indications and Dose section above.

PDF page 77

Adult

500 mL daily for 2 doses; ﬁrst dose of

First-line fragment. Read the complete Indications and Dose section above.

PDF page 77

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Macrogol 3350 with anhydrous sodium sulfate, ascorbic acid, potassium chloride, sodium ascorbate and sodium chloride

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 77

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 77

Contra Indications

Disorders of gastric emptying. G6PD deﬁciency. gastrointestinal obstruction. gastrointestinal perforation. ileus. toxic megacolon

PDF page 77

Cautions

PDF page 77

Prescribing And Dispensing Information

PDF page 77

Safety

Interactions

→Appendix 1: bowel cleansing preparations

PDF page 77

Side Effects

PDF page 77

Pregnancy

Manufacturer advises use only if essential— no or limited information available.

PDF page 77

Breast Feeding

Manufacturer advises use only if essential—no information available.

PDF page 77

Renal Impairment

Manufacturer advises caution if eGFR less than 30 mL/minute/1.73 m2.

PDF page 77

Monitoring Requirements

PDF page 77

Dose and formulations

Directions For Administration

PDF page 77

Medicinal Forms

PDF page 77

Clinical care

Patient And Carer Advice

Manufacturer advises solid food should not be taken during treatment until procedure completed.

PDF page 77

Dose text by age group

Adult

1 litre daily for 2 doses; ﬁrst dose of

First-line fragment. Read the complete Indications and Dose section above.

PDF page 77

Adult

500 mL daily for 2 doses; ﬁrst dose of

First-line fragment. Read the complete Indications and Dose section above.

PDF page 77

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.